![Jennifer Carver](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jennifer Carver
Direttore/Membro del Consiglio presso REVELATION BIOSCIENCES, INC.
Patrimonio netto: 205 $ in data 31/05/2024
Posizioni attive di Jennifer Carver
Società | Posizione | Inizio | Fine |
---|---|---|---|
REVELATION BIOSCIENCES, INC. | Direttore/Membro del Consiglio | 01/05/2020 | - |
Independent Dir/Board Member | 01/05/2020 | - | |
Revelation Biosciences Sub, Inc.
![]() Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Jennifer Carver
Precedenti posizioni note di Jennifer Carver
Società | Posizione | Inizio | Fine |
---|---|---|---|
Kartos Therapeutics, Inc.
![]() Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | Direttore operativo | 01/02/2020 | 01/06/2021 |
LA JOLLA PHARMACEUTICAL COMPANY | Direttore operativo | 01/01/2017 | 23/11/2019 |
Corporate Officer/Principal | 01/02/2014 | 01/01/2017 | |
SPECTRUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2012 | 01/01/2014 |
Allos Therapeutics, Inc.
![]() Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Corporate Officer/Principal | 01/01/2001 | 01/01/2012 |
Formazione di Jennifer Carver
The University of Colorado | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Posizioni
Corporate Officer/Principal | 3 |
Chief Operating Officer | 2 |
Director/Board Member | 2 |
Settori
Health Technology | 7 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
SPECTRUM PHARMACEUTICALS, INC. | Health Technology |
REVELATION BIOSCIENCES, INC. | Health Technology |
Aziende private | 4 |
---|---|
La Jolla Pharmaceutical Co.
![]() La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
Allos Therapeutics, Inc.
![]() Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
Kartos Therapeutics, Inc.
![]() Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy. | Health Technology |
Revelation Biosciences Sub, Inc.
![]() Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | Health Technology |
- Borsa valori
- Insiders
- Jennifer Carver
- Esperienza